TAT 2018 - Targeted Anticancer Therapies

Oncology Meeting Resources

05 Mar - 07 Mar 2018, Paris, France

TAT 2018

TAT 2018 - Targeted Anticancer Therapies focuses on early-phase development and translational research. The programme covered targeted agents, immuno-oncology and combinations involving such agents. Presentations and webcasts from the TAT 2018 - Targeted Anticancer Therapies are available here to ESMO members.

Watch ESMO video reports from experts:

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme | Future ESMO meetings





Format available

https://oncologypro.esmo.org/Meeting-Resour...Therapies/Combining-PARP-inhibitors-with-CPI

Immunotherapy has shifted the treatment paradigm for many malignancies, but not all cancer types have enjoyed a clinically meaningful response from checkpoint blockade.

Date: 06 Mar 2018
Presenter: Filipa Lynce
Resources: Abstract, Presentation, Webcast
Topic: Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...8-Targeted-Anticancer-Therapies/MDICT-report

The ‘Methodology for the Development of Innovative Cancer Therapies’ (MDICT) task force was originally established in 2006 to provide practical guidance on the development of anticancer targeted agents.

Date: 06 Mar 2018
Presenter: Lesley Seymour
Resources: Abstract, Presentation, Webcast
Topic: Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...atients-with-Relapsed-or-Refractory-Lymphoma

NF-kB has been found to be constitutively activated in many lymphomas, such as diffuse large B-cell lymphomas (DLBCL), particularly the ABC subgroup. In preclinical studies, CPI-0610, a BET specific...

Date: 06 Mar 2018
Presenter: Adrian Senderowicz
Resources: Abstract, Presentation, Webcast
Topics: Anticancer agents, Lymphomas, Haematological Malignancies

https://oncologypro.esmo.org/Meeting-Resour...ary-Safety-in-Patients-with-B-Cell-Lymphomas

EZH2 is the catalytic subunit of the PRC2 complex, and plays an important role in transcriptional repression. EZH2 over-expression is correlated with poor prognosis.

Date: 06 Mar 2018
Presenter: Adrian Senderowicz
Resources: Abstract, Presentation, Webcast
Topics: Anticancer agents, Lymphomas, Haematological Malignancies

https://oncologypro.esmo.org/Meeting-Resour...s-Implications-for-design-of-clinical-trials

It has been shown that mutations alone are not the sole determinant of response to targeted agents, for example, BRAF mutations predict response to BRAF inhibitors in melanoma but not colon cancer due...

Date: 06 Mar 2018
Presenter: Udai Banerji
Resources: Abstract, Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...-5461-in-Patients-with-Advanced-Solid-Tumors

G-quadruplexes are secondary DNA structures that reversibly form in guanine-rich regions that can lead to replication fork collapse and double-stranded DNA breaks.

Date: 06 Mar 2018
Presenter: John Hilton
Resources: Abstract, Presentation, Webcast
Topic: Anticancer agents

https://oncologypro.esmo.org/Meeting-Resour...-a-metabolic-co-dependency-for-brain-cancers

Oncogenic mutations in growth factor receptor signaling pathways are common in cancer, including in tumors that arise from or metastasize to the brain. However, most small-molecule inhibitors targeting...

Date: 06 Mar 2018
Presenter: Genaro Villa
Resources: Abstract
Topics: , Central Nervous System Malignancies, Translational Research

https://oncologypro.esmo.org/Meeting-Resour...nticancer-Therapies/Glioma-and-IDH-targeting

Approximately 80% of WHO grade II and III gliomas, and secondary glioblastomas (representing 25% of adult diffuse gliomas overall) harbor mutations in the metabolic isocitrate dehydrogenase enzymes encoded by the IDH1/2 genes.

Date: 06 Mar 2018
Presenter: Daniel Cahill
Resources: Abstract
Topics: Anticancer agents, Central Nervous System Malignancies

https://oncologypro.esmo.org/Meeting-Resour...ginine-Deprivation-in-ASS1-Deficient-Cancers

Argininosuccinate Synthetase 1 (ASS1) is silenced in ∼90% of sarcomas. Loss of this urea cycle enzyme causes cells to become dependent upon extracellular arginine for continued cell growth and proliferation.

Date: 06 Mar 2018
Presenter: Brian Van Tine
Resources: Abstract, Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...-cell-metabolism-and-metabolic-reprogramming

Date: 06 Mar 2018
Presenter: Jonathan Powell
Resources: Presentation, Webcast